PTH and PTH-related protein (PTHrP) are key mediators of skeletal development and homeostasis through their activation of the PTH-1 receptor. Previous studies have found that several AP-1 family members are regulated by PTH, such as c-fos, fra-1, and c-jun. There are numerous genes in the bone microenvironment that contain AP-1 sites, and different Fos family members are reported to have opposing transcriptional activities at AP-1 sites. The purpose of this study was to identify the effects of PTH on expression of the AP-1 protein complex member, fra-2, to extend our understanding of transcriptional regulators of PTH action. PTH induction of fra-2 messenger RNA (mRNA) levels in MC3T3-E1 preosteoblastic cells was maximal with 0
or (53-84). Cycloheximide treatment induced fra-2 expression, and actinomycin D inhibited basal and PTHrP-induced expression. AP-1 protein in nuclear extracts of MC3T3-E1 cells was increased with PTH treatment at 3 h and consisted of high levels of Fra-2 protein, as evidenced by a supershift in an electrophoretic mobility shift assay and Western blot analysis. Up-regulation of steady-state fra-2 mRNA was also noted in vivo, where injection of PTH (1-34) (20 g) resulted in a more-than-7-fold maximal increase in fra-2 mRNA expression in the calvaria of mice, after 1 h of treatment. These data add to the transcriptional mediators induced by PTH and suggest that the interplay of AP-1 family members will provide insight into regulatory pathways of PTH and PTHrP for their anabolic and catabolic actions in bone. (Endocrinology 142: 1975 (Endocrinology 142: -1981 (Endocrinology 142: , 2001 ) P TH IS THE major systemic calcium-regulating hormone with well-documented anabolic and catabolic effects in bone. PTH-related protein (PTHrP) is a regulator of cartilage development, where it is thought to promote proliferation of growth plate chondrocytes (1, 2) . Although animal studies of PTH and PTHrP action have provided insight into their actions in skeletal tissues, the mechanisms of their effects are still unclear. A better understanding of the downstream events in signaling of the PTH-1 receptor is necessary to clarify anabolic and catabolic actions in bone.
The c-fos protooncogene is an immediate-early response gene that undergoes rapid transcriptional activation by PTH (3) (4) (5) . When PTH is administered to rats in vivo, messenger RNA (mRNA) for c-fos is detected in PTH-1 receptor bearing cells within 1 h of administration (6, 7) . It is clear that c-fos plays a major role in bone. Early in development, c-fos is expressed primarily in the growth regions of developing cartilage and bone. Mice with ablation of the c-fos gene develop osteopetrosis and lack osteoclasts; and mice that overexpress c-fos develop chondroblastic osteosarcomas (8, 9) .
To date, seven proteins are included in the AP-1 family of transcription factors (10) . Before binding DNA, Fos proteins (c-Fos, FosB, Fra-1, and Fra-2) form heterodimers with Jun proteins (c-Jun, Jun B, and Jun D) through a leucine zipper motif (11) . AP-1 sites are located in the promoters of several genes expressed by osteoblasts, including osteocalcin, interleukin-6, and macrophage colony-stimulating factor (12) (13) (14) . Expression of Jun and Fos family members is modulated during osteoblast proliferation and differentiation; and recently, these proteins have been shown to be key mediators in the positive regulation of bone formation (15) (16) (17) . Nuclear proteins for all of the AP-1 family members are high during osteoblast proliferation. During differentiation, levels decline, and Fra-2 and Jun D are the principal proteins present (18) . Modulation of Fra-2 expression by overexpression or antisense oligonucleotide treatment suggests that Fra-2 is an important factor involved in the development of the mature osteoblast phenotype. Most studies have focused on the ability of PTH to stimulate c-fos or c-jun gene expression, but other AP-1 family members may also be regulated by PTH. PTH has also been found to increase fra-1, fos B, and jun-B (19) , but there are no reports regarding the effects of PTH on fra-2. The purpose of this study was to evaluate the effects of PTH on fra-2 expression in bone in vitro and in vivo.
Materials and Methods

Cell culture
MC3T3-E1 cells were obtained from Dr. M. Kumegawa via Dr. Renny Franceschi (University of Michigan, Ann Arbor, MI) and maintained as described (20) . Primary murine calvarial cells were isolated via collagenase digestion as described, and the third digest was used without passage (21) . Cells were plated at 50,000/cm 2 in ␣-modified Eagle's medium with 10% FBS, 100 U/ml penicillin, and streptomycin and were induced to differentiate (4 -7 days) for maximal PTH-1 receptor expression (21) with the addition of 50 g/ml l-ascorbic acid (Fisher Scientific, Itasca, IL) and 10 mm ␤-glycerophosphate (Sigma, St. Louis, MO).
Gene expression studies in vitro
Total RNA was isolated from MC3T3-E1 or primary murine calvarial cells treated with various doses of PTH (1-34) for 0 -24 h. Northern blot analyses were performed as described (4) . Briefly, total RNA was isolated by the guanidinium isothiocyanate method and quantified by spectrophotometry. Total RNA (10 g) was electrophoresed on 1.2% agarose-formaldehyde gels, transferred to nylon membranes (Duralon U.V.; Stratagene, La Jolla, CA), and cross-linked with UV light. Nylon membranes were hybridized with a complementary DNA probe for fra-2 (18) or c-fos (4) labeled with [␣-32 P] deoxycytidine triphosphate, using random primer labeling (Amersham Pharmacia Biotech, Piscataway, NJ). Blots were stripped and reprobed with a complementary DNA for 18S ribosomal RNA (22) to control for RNA loading. After hybridization and washing, radioactive cpm were quantified using an Instant Imager (Packard Instrument Co., San Diego, CA). Blots were also exposed to Biomax or X-OMAT film (Eastman Kodak Co., Rochester, NY) at Ϫ80 C for 24 -72 h, and band intensity was determined by image analysis. processed using a mortar and pestle for RNA isolation, as described (23) . Northern blot analysis was performed as above.
Gene expression studies in vivo
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated from MC3T3-E1 cells stimulated with PTH (1-34) (0.1 m) or PTHrP (1-34) (0.1 m) for 3 h, via hypotonic lysis, as described (24) . Protein concentrations were determined by the Bradford assay (Pierce Chemical Co., Rockford, IL). Nuclear extracts (2.5 g) were incubated, for 20 min at 24 C, with 50,000 cpm 32 P-end labeled (T 4 -polynucleotide kinase; Amersham Pharmacia Biotech) AP-1 oligonucleotide (CGCTTGATGAGTCAGCCGGAA) with or without an excess of unlabeled competitor oligonucleotide. For supershift experiments, antibodies (4 g) for Fra-2, Fra-1, Fos, FosB (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and cAMP response element binding protein (CREB) (Rockland Immunochemicals, Gilbertsville, PA) were added to binding reactions and incubated overnight on ice. The samples were loaded on prerun (30 min; 150 V) 5% polyacrylamide gels and run for 3 h at 150V at 4 C. Gels were dried and exposed to films (4 -10 h) at Ϫ80 C.
Western blot analysis
Nuclear extracts (30 g/lane) were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membrane (Trans-blot transfer medium, Bio-Rad Laboratories, Inc., Hercules, CA). Membranes were blocked in 7% nonfat dried milk in Tris-buffered saline (TBS) overnight at 4 C. After two washes in TBS plus 0.05% Tween-20, membranes were incubated overnight at 4 C in a 1:100 dilution of Fra-2 antibody (Santa Cruz Biotechnology, Inc.) in TBS plus 1% BSA. Membranes were washed four times in TBS and incubated for 45 min with secondary antibody. After three washes in TBS, blots were developed by chemiluminescent 
Results
PTH-induced fra-2 expression in vitro
PTH treatment (1-2 h) stimulated an increase in steadystate mRNA for fra-2 in MC3T3-E1 osteoblastic cells and primary murine calvarial cell cultures (Fig. 1) . Detectable increases were noted at a dose of 10 pm and were greater than 4-fold at 1 m. The level of c-fos mRNA, a known PTHregulated transcription factor (4), in the same cell cultures was also dose dependently increased. Relative to fra-2 expression, PTH-induced c-fos expression was an average of 2-fold higher at concentrations greater than 100 pm. An investigation of the time response of fra-2 mRNA expression to PTH (1-34)-treatment indicated that gene expression was rapid, with maximal increase at 1 h. (Fig. 2) . The PTH-stimulated up-regulation in fra-2 mRNA gene expression was found with PTH (1-34) but not with PTH or PTH (53-84) (Fig. 3) . PTHrP (1-34) stimulated fra-2 at equivalent doses as PTH and forskolin-treatment also stimulated fra-2 expression (data not shown).
To evaluate the molecular mechanisms of PTH-stimulated fra-2 induction, transcriptional and translational regulators were used. The protein synthesis inhibitor, cycloheximide (CHX), was administered to osteoblastic cultures, with or without PTHrP stimulation (Fig. 4A) . CHX alone led to an induction of fra-2 mRNA typical of an immediate early response gene. CHX in combination with PTHrP also resulted in high levels of fra-2 expression, with a trend toward increased expression vs. CHX alone. Actinomycin D pretreatment (1 h) of MC3T3-E1 cells resulted in an abrogation of PTHrP stimulation of fra-2 mRNA after 3 h (Fig. 4, B and C) , suggesting that the PTHrP effect is dependent on transcription.
PTH-induced fra-2 expression in vivo
A single administration of PTH (20 g) over the calvaria of mice was effective in inducing an increase of more than 7-fold in steady-state fra-2 mRNA expression in bone vs. vehicle-injected or noninjected controls (Fig. 5) . The time response for fra-2 induction in vivo is demonstrated in Fig. 6 . There was maximal expression of steady-state fra-2 mRNA 1 h after injection; and by 8 h, levels returned to baseline values. The expression of c-fos in these calvaria followed a pattern similar to that of fra-2.
PTH induces AP-1 DNA binding activity and Fra-2 protein
To determine whether the PTH-induced fra-2 gene expression resulted in an increase in AP-1 binding activity and specifically an increase in nuclear fra-2 protein, EMSAs were performed. Extracts from PTH-and PTHrP-treated MC3T3-E1 cells were incubated with an oligonucleotide probe containing the consensus AP-1 sequence. Figure 7 shows that PTH and PTHrP treatment both resulted in a shift in the AP-1 binding that was indicative of an increase in the nuclear accumulation of AP-1 protein. This shift was nearly abolished with the addition of 0.25 g unlabeled AP-1 oligonucleotide. A strong Fra-2 supershift was present in both PTH-and PTHrP-treated cultures, supporting the finding of Fra-2 protein in the nucleus 3 h after treatment. A detectable, but much lighter, supershift was also present with an antibody to CREB. At 8 h after PTHrP-treatment, AP-1 shift and supershifted nuclear protein levels of Fra-2 were reduced, compared with 3 h, and were similar to control levels (Fig.  7B ). In comparison with other Fos family members (c-Fos, Fos B, and Fra-1), Fra-2 was the most highly expressed 3 h after PTHrP treatment (Fig. 8) . Western blot analysis confirmed the specific up-regulation of Fra-2, at the protein level, with PTH and PTHrP treatment (Fig. 9 ).
Discussion
AP-1 is one of the most widely studied transcription factors. The AP-1 protein components are encoded by immediate-early genes, and AP-1 binding sites are found in numerous genes. Examples of genes containing AP-1 sites that are important in bone are osteocalcin, type I collagen, interleukin-6, M-CSF, and collagenase-3 (12-14, 25, 26) . Findings that PTH modulates members of the AP-1 family is likely to be important for the biologic activities of PTH and PTHrP. It is well known that PTH up-regulates c-fos; but, to our knowledge, effects of PTH or PTHrP to stimulate fra-2 in bone have not been well described.
The sequences of c-fos and fra-2 are very similar, with highly conserved intron-exon structures (27) . The similarity of structure suggests that both originated from a single ancestral gene. In concert with this, Fra-2 and Fos proteins are able to form heterodimers with Jun family members (28, 29).
Additionally, Fra-2 can support osteoclast differentiation in place of c-Fos; although to a much lower extent than c-Fos or Fra-1 (30) . Evaluation of fra-2 during development indicates that expression is high in bone but has a different spatial distribution than c-fos. Specifically, in situ hybridization for fra-2 revealed expression in the bony and cartilaginous side of the growth plate and not in the perichondrium during embryonic development, whereas c-fos is expressed in the perichondrial growth region of the cartilaginous skeleton (31) . Functionally, other differences have been noted in keratinocytes, where Fra-2:Jun B heterodimers negatively regulate AP-1-mediated gene expression but c-Fos:Jun B het- erodimers activate AP-1 transcriptional activity (32) . In contrast, in osteoblasts, overexpression of fra-2 and jun-D activates (while c-fos and c-jun suppress) osteocalcin expression (18, 33) . Because many genes expressed during both proliferation and differentiation stages contain AP-1 target sequences, mechanisms for both the induction and suppression of gene expression through AP-1 sites are likely to be operative in bone. This may also explain the diversity of effects PTH has on genes active in the bone microenvironment that contain AP-1 sites.
Interestingly, the studies reported here indicate differences of PTH induction of fra-2, comparing in vitro and in vivo experiments. A higher dose of PTH is required to stimulate gene expression of fra-2 than c-fos in vitro. Detectable and significant levels of c-fos are induced with as little as 1.0 pm PTH (1-34) (4); whereas increases in fra-2 seem to require a higher dose. However, the in vivo studies resulted in similar levels of expression of c-fos and fra-2 with PTH injection. Similarly, the time course of PTH-mediated fra-2 expression in vitro is different from that reported for c-fos or c-jun (3, 4) . The increase in fra-2 expression in vitro is maintained over a longer time period than that of c-fos or c-jun. The significance of this duration effect is unclear, but it suggests that AP-1 family members likely have distinct roles in response to extracellular signals in the bone microenvironment. Given the reported negative influence of Fra-2 and Jun D on collagenase expression (34), Fra-2 could be involved in a negative feedback response to PTH effects. Other in vitro studies, comparing c-fos and fra-2 expression in fibroblasts, noted that both were induced by phorbol ester but that fra-2 transcripts were delayed, relative to c-fos (35) . The delayed expression of fra-2 may be explained by findings that c-fos is responsible, in part, for the up-regulation of fra-2 because of AP-1 sites in the fra-2 promoter (36). Data are sparse regarding the induction of fra-2 in vivo, especially relative to its induction by PTH in bone.
The translation of PTH-induced fra-2 mRNA into protein was evidenced by Western blot analysis and gel shift analysis, which demonstrated increased AP-1 consensus site binding of nuclear extracts from PTH-treated cells vs. vehicle-treated cells. The Fra-2 protein comprised a large portion of the AP-1 shifted band, as evidenced by the strong supershift with a Fra-2 antibody. This suggests that Fra-2 could play a major role in PTH effects in osteoblasts. Similar to previous reports, a CREB antibody was also capable of supershifting the PTH-induced AP-1 shift (37); although this was minimal, compared with the Fra-2 response. CREB has been reported to interact at AP-1 sites and repress AP-1 transcriptional activity (32, 38) .
During osteoblast differentiation, Fra-2 and Jun D are the most abundant AP-1 family members, and inhibition of fra-2 with antisense oligonucleotides results in a suppression of osteoblast differentiation (18) . This suggests that PTH may act on osteoblasts to promote differentiation through stimulation of fra-2. However, because we and others have previously reported that PTH inhibits osteoblast differentiation in vitro (39, 40) , coinduction of other AP-1 family members such as fra-1 or c-jun, or unrelated transcription factors, may be responsible for counteracting this effect of fra-2. Recent evidence indicates that PTH regulates the collagenase-3 promoter via the interaction of the AP-1 site and the runt binding domain site in UMR 106 -01 cells (37) . Overexpression of c-fos, c-jun, osteoblast-specific factor-2, and core binding factor-␤ increased the response to PTH in UMR 106 -01 cells; whereas overexpression of Fra-2 and Jun D decreased basal and PTH-induced collagenase-3 activity in primary osteoblasts (34) . Although little information is available regarding the induction of fra-2 by PTH in this model, our data similarly support findings that other AP-1 family members, such as fra-2, may be responsible for PTH effects on downstream target genes.
The identification of fra-2 up-regulation, both in vitro and in vivo, is a valuable addition to the repertoire of transcriptional mediators induced by PTH. Furthermore, these data indicate that complex changes in AP-1 member binding to DNA is likely active in the signaling of PTH to evoke its anabolic and catabolic actions in bone.
